Lyell Immunopharma, Inc. (LYEL)
NASDAQ (NGS) NASDAQ (NGS) Primary Summary
Down 27% in 4 Weeks, Here's Why Lyell Immunopharma (LYEL) Looks Ripe for a Turnaround
Lyell Immunopharma (LYEL) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Wall Street Analysts Think Lyell Immunopharma (LYEL) Could Surge 176.02%: Read This Before Placing a Bet
The average of price targets set by Wall Street analysts indicates a potential upside of 176% in Lyell Immunopharma (LYEL). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Lyell Immunopharma, Inc. (LYEL) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Lyell Immunopharma, Inc. (LYEL) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Lyell Immunopharma, Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| KJD Kathryn J. Daniels Canada Pension Plan Investment Board | 29,411 | $319,231.06 | $238,817.32 | -$80,413.74 | -25.19% |
| CD Charlie Durham Sterling Capital Management LLC | 190 | $2,422.5 | $1,518.1 | -$904.4 | -37.33% |
 Point72 Asset Management LP Point72 Asset Management LP | 26,080 | $611,229.94 | $213,595.2 | -$397,634.74 | -65.05% |
 Joseph Castro Nuveen LLC | 12,595 | $160,586.25 | $100,634.05 | -$59,952.2 | -37.33% |
 Jennifer Grunberg Allspring Global Investments Holdings LLC | 16,145 | $205,848.75 | $132,227.55 | -$73,621.2 | -35.76% |
Lyell Immunopharma, Inc. (LYEL) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Lyell Immunopharma, Inc. ever had a stock split?
Lyell Immunopharma, Inc. Profile
| Biotechnology Industry | Healthcare Sector | Lynn Seely CEO | NASDAQ (NGS) Exchange | 55083R203 CUSIP |
| US Country | 161 Employees | - Last Dividend | 2 Jun 2025 Last Split | 17 Jun 2021 IPO Date |
Overview
Lyell Immunopharma, Inc. is a trailblazer in the field of cell therapy, taking bold strides within the realm of clinical-stage development to innovate treatments for patients burdened by solid tumors. Rooted in the power of T cell reprogramming technologies, this company leverages advanced genetic and epigenetic approaches to craft solutions designed to combat cancer more effectively. Since its establishment in 2018, Lyell Immunopharma has positioned its headquarters in South San Francisco, California, where it continues to push the boundaries of how cancer is treated, embodying a beacon of hope for countless individuals facing this daunting adversary.
Products and Services
Lyell Immunopharma, Inc. is at the forefront of developing transformative therapies through a portfolio of both clinical-stage and preclinical product candidates, each designed with the intent to revolutionize the treatment of solid tumors.
- LYL797: This innovative product candidate stands out as a genetically and epigenetically reprogrammed ROR1 chimeric antigen receptor (CAR) T cell therapy. Currently under evaluation in a Phase 1 clinical trial, LYL797 aims to provide a targeted treatment option against a variety of solid tumors, showcasing the company’s commitment to advancing care through precision medicine.
- LYL845: Representing a novel approach in the solid tumor treatment landscape, LYL845 is an epigenetically reprogrammed tumor-infiltrating lymphocytes (TIL) product. Sitting in Phase 1 clinical trials, this candidate zeroes in on multiple solid tumor indications, potentially setting a new standard for responsiveness and effectiveness in solid tumor therapy.
- Preclinical Product Candidates: Alongside its clinical-stage products, Lyell Immunopharma is nurturing a pipeline of preclinical candidates, such as LYL119. This ROR1 CAR T-cell product candidate is engineered for enhanced cytotoxicity against solid tumors. Also in development is a second-generation TIL product, further underscoring the company’s dedication to pioneering within the field of oncology.
Contact Information
